Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THARROS study of Trixeo Aerosphere versus Bevespi Aerosphere in COPD with cardiovascular risk
2023-507407-59-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Trixeo Aerosphere arm with Bevespi Aerosphere arm (2 arms). Primary endpoint: Time to first severe cardiac or COPD event. Planned start Jul 2024; status: authorised.
02
Drugs
budesonideBEVESPI AEROSPHERE
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2023-507407-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507407-59-00.